Menu Close

Asterias Biotherapeutics’ stem cell-derived treatment for spinal cord injury holds promise: 4 things to know

Asterias Biotherapeutics provided an update from its ongoing phase 1/2a clinical trial of a stem cell treatment for severe spinal cord injury. Here are four things to know: 1. The SCiStar study involves three escalating doses of AST-OPC1 involves three … (본문 전체 8/2/2018 7:04 AM)